Two leading experts took to the stage during ANZAN ASM to debate a controversial topic in neurology – should high-expense high potency MS therapy be used first-line in patients with MS? Taking on the ‘yes’ side of the debate Associate Professor Tomas Kalincik from the Royal Melbourne Hospital told delegates that recent statistics showed the ...
Great debate: Should potent and expensive MS therapy be used first line?
By Nicola Garrett
28 May 2019